Portuguese biotech company SilicoLife secures Series A investment of up to €9.8 million to accelerate the biological production of ingredients.

No items found.
December 13, 2022

On the past December 7 SilicoLife(www.silicolife.com) concluded the first of two Series A rounds fundraising to the tune of €4.9 million, covered in its entirety by funds managed by venture capital firm BlueCrow (www.bluecrowcapital.com).

In line with the approved objective-basedprogram for the next 24 months, BlueCrow is committed to securing asecond, equally sizable, round of investment in SilicoLife. The tworounds of investment are aimed at supporting the development and evolution ofthe company's business model over the next 3 to 5 years.

SilicoLife combines AI (artificial intelligence) and Biology to further thesustainable production of various ingredients, using precision fermentation andmicroorganism engineering.

With a strong track record in creatingoptimized biological solutions for leading companies across different sectorsof activity, SilicoLife will focus on creating its own line of productiontechnologies within the dietary supplements industry.

Biotechnology, particularly with thedevelopments from the last decades, offers tools that allow innovations withmultiple applications. From it, the development of products and solutions inareas such as medicine, agriculture, livestock, food, bioenergy, chemicalindustry, among others, becomes possible, allowing not only the production ofcompounds that until then could only be extracted from non-sustainable sources,but also the replacement of highly polluting chemical processes - but essentialfor modern society - by sustainable and scalable alternatives.

In a nutshell, SilicoLife's approach is, in arational way and on a basis of strong knowledge, to design industrialmicroorganisms to produce, in a profitable and sustainable way, the ingredientsand supplements that are part of our daily lives.

Simão Soares, the CEO of SilicoLife, adds: "Fermentation is themanufacturing technology of the future. We are leveraging our technologicalexpertise and experience in developing new biological processes to address thecurrently unmet needs of the high-growth supplement industry. The cooperationbetween SilicoLife and BlueCrow combines our recognized expertise in R&Dwith the financial strength and scope of the funds managed by BlueCrow to scaleand potentiate a knowledge-based company."

BlueCrow further stated, “We’ve been following SilicoLife's business model for some time and we understand the conditions are in place for this team to consolidate the experience and knowledge they’ve acquired over the last several years to face their next series of challenges, designing and creating solutions of enormous impact."

To face this new phase, SilicoLife will soon announce job openings in the areas of software engineering, molecular biology, strain engineering, and business development, amongst others.

Related Articles

No items found.